Skip to main content
. 2022 Nov 5;14(21):5449. doi: 10.3390/cancers14215449

Figure 2.

Figure 2

Isogenic melanoma models are resistant to BRAF inhibitors but not to BRAF non-specific chemotherapeutics in 2D tissue culture. (A) Dabrafenib resistance of A375 melanoma models in 2D tissue culture; (B) Vemurafenib resistance of A375 melanoma models in 2D tissue culture; (C) No resistance to the BRAF non-specific chemotherapeutic doxorubicin in 2D tissue culture; (D) Immunoblot demonstrating BRAF inhibitor resistance in EGFR pathway signaling in NRAS Q61K and KRAS G13D A375 melanoma models. Cells were treated with 1.0 μM of the indicated drug for 90 min prior to harvesting protein; (E) Dose-response curve for the MEK inhibitor trametinib in the MEK1 Q56P melanoma model in 2D tissue culture; (F) The same curve as in (E) for the MEK inhibitor binimetinib.